<DOC>
	<DOC>NCT01066845</DOC>
	<brief_summary>To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice －focused topics－ 1. To evaluate the incidence of adverse events for the patients with long-term use 2. To evaluate the incidence of adverse events of decreased blood pressure, bleeding (including uterine hemorrhage), visual disturbance and sudden hearing loss.</brief_summary>
	<brief_title>Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Patients with PAH receiving Adcirca Patients who meet the criteria of contraindication patients with hypersensitivity to tadalafil patients who are using any form of organic nitrate patients with severe renal impairment patients with severe hepatic impairment patients taking strong inhibitors of CYP3A4 patients taking strong inducers of CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>